Vaxil Bio Ltd. | Balance Sheet

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
0.40
35.50
12.00
1,023.00
169.00
753
Total Accounts Receivable
3.70
3.10
25.00
26.00
13.00
57
Other Current Assets
-
2.70
-
3.00
10.00
18
Total Current Assets
4.10
41.30
37.00
1,052.00
192.00
828
Net Property, Plant & Equipment
267.10
211.60
23.00
165.00
118.00
62
Other Assets
-
-
230.00
-
-
-
Total Assets
271.20
252.90
290.00
1,217.00
310.00
890
ST Debt & Current Portion LT Debt
-
-
-
17.00
29.00
Accounts Payable
1.20
-
-
-
-
Other Current Liabilities
197.80
65.00
507.00
460.00
719.00
Total Current Liabilities
199.00
65.00
507.00
477.00
748.00
Long-Term Debt
-
-
-
84.00
49.00
Total Liabilities
199.00
65.00
507.00
561.00
797.00
Common Equity (Total)
72.10
187.90
217.00
656.00
487.00
Total Shareholders' Equity
72.10
187.90
217.00
656.00
487.00
Total Equity
72.10
187.90
217.00
656.00
487.00
Liabilities & Shareholders' Equity
271.20
252.90
290.00
1,217.00
310.00

About Vaxil Bio

View Profile
Address
First Canadian Place, 34th Floor
Toronto Ontario M5X 1A9
Canada
Employees -
Website http://vxlbio.com
Updated 07/08/2019
Vaxil Bio Ltd. engages in the development of immunotheraphies such as neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. Its pipeline consists of ImMucin, SPmAb2, SPmAb6, and MTbuVax. The company was founded on September 13, 2013 and is headquartered in Toronto, Canada.